• 1
    Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130(2S Suppl.): 396S402S.
  • 2
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95(5): 12318.
    Direct Link:
  • 3
    Barone C, Pettinato R, Avola E, et al. Comparison of three probiotics in the treatment of acute diarrhea in mentally retarded children. Minerva Pediatr 2000; 52(3): 1615.
  • 4
    Gomez-Gil B, Roque A, Turnbull JF, Inglis V. A review on the use of microorganisms as probiotics. Rev Latinoam Microbiol 1998; 40(3–4): 16672.
  • 5
    Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000; 30(1): 5460.
  • 6
    Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr 1998; 27(3): 32332.
  • 7
    Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95(1 Suppl.): S24.
  • 8
    Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000; 95(1 Suppl.): S168.
  • 9
    Hahn B, Watson M, Yan S, Gunput D, Heuijerjans J. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998; 43(12): 27158.
  • 10
    Cremonini F. Performance characteristics of scintigraphic gastrointestinal and colonic transit measurements in health: normal values and reliability. Gastroenterology 2002; 122: A1061(Abstract).
  • 11
    Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65(11): 145679.
  • 12
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32(9): 9204.
  • 13
    Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994; 19(1): 2830.
  • 14
    Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32(1): 739.
  • 15
    Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33(6): 81824.
  • 16
    Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000; 119(1): 4150.
  • 17
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13(9): 114959.
  • 18
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355(9209): 103540.
  • 19
    Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257(2 Part 1): G28490.
  • 20
    Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990; 258(6 Part 1): G85662.
  • 21
    Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36(5): 60915.
  • 22
    Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103(1): 3642.
  • 23
    Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy with labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38(11): 180710.
  • 24
    Pratt JW. Remarks on zeros and ties in the Wilcoxon signed rank procedures. J Am Statist Assoc 1959; 54(287): 65567.
  • 25
    Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecol Health Dis 2001; 13: 2126.
  • 26
    Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrne S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993; 59(1): 1520.
  • 27
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352(9135): 11879.
  • 28
    Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94(5): 13206.
    Direct Link:
  • 29
    Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48(1): 149.
  • 30
    Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991; 101(1): 10715.
  • 31
    Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24(5): 40511.
  • 32
    Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94(10): 292935.
    Direct Link:
  • 33
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118(3): 4638.
  • 34
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15(10): 165566.
  • 35
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(2): 3059.
  • 36
    Mimura T, Fernando R, Schreiber S, et al. Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 2002; 122: A81.
  • 37
    Lammers K, Vergopoulos A, Babel N, et al. Probiotic therapy as a prophylaxis in ileo-anal anastomosis patients decreases interferon gamma, interleukin 1 beta and interleukin 8 mRNA expression. Gastroenterology 2002; 122: A274.